Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody.

Fifty-two patients with epithelial ovarian cancer were treated with yttrium-90-labelled monoclonal antibody HMFG1 administered intraperitoneally following conventional surgery and chemotherapy as part of an extended phase I-II trial. The treatment was well tolerated and the only significant toxicity...

Descripción completa

Detalles Bibliográficos
Autores principales: Hird, V., Maraveyas, A., Snook, D., Dhokia, B., Soutter, W. P., Meares, C., Stewart, J. S., Mason, P., Lambert, H. E., Epenetos, A. A.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1993
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968585/
https://www.ncbi.nlm.nih.gov/pubmed/8347497
_version_ 1782134772599881728
author Hird, V.
Maraveyas, A.
Snook, D.
Dhokia, B.
Soutter, W. P.
Meares, C.
Stewart, J. S.
Mason, P.
Lambert, H. E.
Epenetos, A. A.
author_facet Hird, V.
Maraveyas, A.
Snook, D.
Dhokia, B.
Soutter, W. P.
Meares, C.
Stewart, J. S.
Mason, P.
Lambert, H. E.
Epenetos, A. A.
author_sort Hird, V.
collection PubMed
description Fifty-two patients with epithelial ovarian cancer were treated with yttrium-90-labelled monoclonal antibody HMFG1 administered intraperitoneally following conventional surgery and chemotherapy as part of an extended phase I-II trial. The treatment was well tolerated and the only significant toxicity observed was reversible myelosuppression as previously described. Following conventional surgery and chemotherapy, 21 out of the 52 patients had no evidence of residual disease and were regarded as receiving treatment in an adjuvant setting. To date, two of these patients have died of their disease (follow-up 3-62 months, median follow-up 35 months). This extended phase I-II study suggests that patients with advanced ovarian cancer who achieve a complete remission following conventional therapy may benefit from further treatment with intraperitoneal radioactive monoclonal antibody.
format Text
id pubmed-1968585
institution National Center for Biotechnology Information
language English
publishDate 1993
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19685852009-09-10 Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Hird, V. Maraveyas, A. Snook, D. Dhokia, B. Soutter, W. P. Meares, C. Stewart, J. S. Mason, P. Lambert, H. E. Epenetos, A. A. Br J Cancer Research Article Fifty-two patients with epithelial ovarian cancer were treated with yttrium-90-labelled monoclonal antibody HMFG1 administered intraperitoneally following conventional surgery and chemotherapy as part of an extended phase I-II trial. The treatment was well tolerated and the only significant toxicity observed was reversible myelosuppression as previously described. Following conventional surgery and chemotherapy, 21 out of the 52 patients had no evidence of residual disease and were regarded as receiving treatment in an adjuvant setting. To date, two of these patients have died of their disease (follow-up 3-62 months, median follow-up 35 months). This extended phase I-II study suggests that patients with advanced ovarian cancer who achieve a complete remission following conventional therapy may benefit from further treatment with intraperitoneal radioactive monoclonal antibody. Nature Publishing Group 1993-08 /pmc/articles/PMC1968585/ /pubmed/8347497 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Hird, V.
Maraveyas, A.
Snook, D.
Dhokia, B.
Soutter, W. P.
Meares, C.
Stewart, J. S.
Mason, P.
Lambert, H. E.
Epenetos, A. A.
Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody.
title Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody.
title_full Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody.
title_fullStr Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody.
title_full_unstemmed Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody.
title_short Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody.
title_sort adjuvant therapy of ovarian cancer with radioactive monoclonal antibody.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968585/
https://www.ncbi.nlm.nih.gov/pubmed/8347497
work_keys_str_mv AT hirdv adjuvanttherapyofovariancancerwithradioactivemonoclonalantibody
AT maraveyasa adjuvanttherapyofovariancancerwithradioactivemonoclonalantibody
AT snookd adjuvanttherapyofovariancancerwithradioactivemonoclonalantibody
AT dhokiab adjuvanttherapyofovariancancerwithradioactivemonoclonalantibody
AT soutterwp adjuvanttherapyofovariancancerwithradioactivemonoclonalantibody
AT mearesc adjuvanttherapyofovariancancerwithradioactivemonoclonalantibody
AT stewartjs adjuvanttherapyofovariancancerwithradioactivemonoclonalantibody
AT masonp adjuvanttherapyofovariancancerwithradioactivemonoclonalantibody
AT lamberthe adjuvanttherapyofovariancancerwithradioactivemonoclonalantibody
AT epenetosaa adjuvanttherapyofovariancancerwithradioactivemonoclonalantibody

Ejemplares similares